MedTrace Logo

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-11-19

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Conditions

  • Autosomal Dominant Hypocalcemia (ADH)
  • Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

DRUG

Encaleret

Tablets administered orally

Sponsors & Collaborators

  • Calcilytix Therapeutics, Inc., a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Calcilytix Medical Director · Calcilytix Therapeutics, Inc., a BridgeBio company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-20
Primary Completion
2023-09-07
Completion
2023-09-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04581629 on ClinicalTrials.gov